Recombinant Cynomolgus Monkey Klotho beta His Protein, CF

When Recombinant Human FGF-21 (Catalog # 2539-FG) is immobilized at 1 μg/mL (100 μL/well), Recombinant Cynomolgus Monkey Klotho beta His-tag (Catalog # 10428-KB) binds with an ED50 of 0.05-0.4 μg/mL.

2 μg/lane of Recombinant Cynomolgus Monkey Klotho beta His-tag (Catalog # 10428-KB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 110-130 kDa.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey Klotho beta His Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA.

  When Recombinant Human FGF-21 (Catalog # 2539-FG) is immobilized at 1 µg/mL (100 µL/well), Recombinant Cynomolgus Monkey Klotho beta His-tag (Catalog # 10428-KB) binds with an ED₅₀ of 0.05-0.4 μg/mL.

• Source: Mouse myeloma cell line, NS0-derived cynomolgus monkey Klotho beta protein
  Phe53-Leu997, with a C-terminal 6-His tag
• Accession #: EHH53620.1
• N-terminal Sequence: Phe53
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 110 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 110-130 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -70 °C as supplied.
  • 3 months, -70 °C under sterile conditions after opening.
  • 1 month, 2 to 8 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in PBS, Glycerol and EDTA.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey Klotho beta His Protein, CF

• betaKlotho
• beta-klotho
• BKL
• KLB
• klotho beta like
• Klotho beta
• klotho beta-like protein
• MGC142213

Background

Klotho beta (KLB), a divergent structural member of the glycosidase I superfamily, is a type I transmembrane protein expressed primarily in the liver and pancreas, with lower expression in adipose tissue (1). Klotho beta , along with the closely related Klotho, consists of a large extracellular domain (ECD) containing two glycosidase-like regions, a transmembrane domain, and a short intracellular tail. The two glycosidase-like regions of Klotho beta share high homology to the one beta -glycosidase family yet lack the critical active site Glu residues present in beta -glycosidases necessary for catalytic activity, though physiologically relevant enzymatic activity for Klotho beta has been suggested (2, 3). The ECD of mature cynomologus Klotho beta shares 97% and 80% amino acid sequence identity with the ECD of human and mouse Klotho beta , respectively. Similar to Klotho, Klotho beta helps to regulate multiple metabolic processes in mammals by acting as a co-receptor that facilitates binding between FGF19 subfamily members and their receptors (4). The Klotho beta mediated interaction of FGF19 (FGF15 in mouse) with FGF Receptor 4 in the liver negatively regulates bile acid synthesis by controlling the secretion of two key bile acid synthase genes, cholesterol 7- alpha hydroxylase (Cyp7a1) and sterol 12- alpha hydroxylase (Cyp8b1) (5-7). Klotho beta is also a cofactor for the interaction of FGF21 with FGF Receptor 1c in adipocytes, which allows FGF21 to stimulate GLUT1 expression, up-regulating adipocyte insulin-dependent glucose uptake (5 - 8). Regulation of Klotho beta function has been suggested as a therapy for several cardiometabolic diseases (9).

1. Mian, I.S. (1998) Blood Cells Mol. Dis. 24:83.
2. Ito, S. et al. (2000) Mech Dev. 98:115
3. Goetz, R. et al. (2007) Mol. Cell. Biol. 27:3417.
4. Kuro-O, M. (2019) Nat Rev Nephrol. 15:27.
5. Ito, S. et al. (2005) J. Clin. Invest. 115:2202.
6. Kurosu, H. et al. (2007) J. Biol. Chem. 282:26687.
7. Lin, B. C. et al. (2007) J. Biol. Chem. 282:27277.
8. Ogawa, Y. et al. (2007) Proc. Natl. Acad. Sci USA 104:7432.
9. Min, X. et al. (2018) J. Biol. Chem 293:14678.

Bioinformatics

• Uniprot:
  • EHH53620.1()